Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419897 | 1.00 | MAPT (0.43) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL13272460 | 1.00 | MAPT (0.43) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL3419912 | 0.84 | F2RL3 (0.36) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL13272130 | 0.84 | F2RL3 (0.36) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL3419910 | 0.84 | F2RL3 (0.36) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL3060321 | 0.84 | CHEK1 (0.38) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3422710 | 0.84 | ERN1 (0.42) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL13272461 | 0.84 | ERN1 (0.42) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2477838 | 0.84 | CHEK1 (0.38) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3422707 | 0.84 | ERN1 (0.42) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| EP-2170877-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | MAPT 4772/4885ALDH1A1 523/4885LMNA 1045/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | MAPT 4772/4885ALDH1A1 523/4885LMNA 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.